Video

Evaluating efficacy, safety of intracameral dexamethasone 9% vs topical regimen for cataract surgery

Robert Weinstock, MD, discusses the efficacy and safety of intracameral dexamethasone suspension 9% compared to standard of care topical regimen for eyes receiving cataract surgery.

In an interview with Ophthalmology Times,® Robert Weinstock, MD, discussed the efficacy and safety of intracameral dexamethasone suspension 9% (Dexycu; EyePoint Pharmaceuticals Inc.),compared to standard of care topical regimen for eyes receiving cataract surgery.

Weinstock was involved in research into the use of dexamethasone intraocular suspension 9% at the time of cataract surgery.

It is placed inside the capsular bag right at the end of surgery to avoid putting patients on topical surgery.

The option can take the treatment out of the hands of patients, who may already be prescribed multiple drops.

This issue has increased during the pandemic, as elderly patients who might normally have had assistance from family or friends had instead had to obtain and administer ophthalmic drugs on their own, and no longer can rely on that help.

The study included two groups, one which received standard of of care consisting of topical steroid, NSAID and antibiotic.

The other group received intracameral dexamethasone along with topical NSAID and an antibiotic.

“We found that that there was no significant difference in postoperative inflammation scores in the anterior chamber at day one, at one week, and at one month,” he said.

Weinstock noted that the two groups compared equivalent.

“I wanted to do the study because I wanted to provide our colleagues with some real world post-market, post-approval data about how well it works to let everyone know how well it works,” he said.“For routine cataract surgery, this works just as well, at least in my hands so far, for eliminating the need to put people on topical steroids.”

The option eliminates the need to put patients and drops and Weinstock said it is great to have an option that can be used easily during cataract surgery.

The next step, according to Weinstock, would be to broaden the depth of the data and eventuate the procedure across multiple practices. It also would be good to receive feedback from patients.

“We would like to see what the long-term impact is of reducing drops for our patients,” he concluded.

Financial disclosure: Weinstock is a consultant to EyePoint Pharmaceuticals.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.